Jubilant Ingrevia Ltd (JUBLINGREA) Growth Catalysts - Q1 FY27 (Jun-26)
7 growth catalysts flagged by management, 1 new in the recent quarters, 3 no longer discussed.
Reported base: Q1 FY27 revenue reached 15-quarter high of INR1,300 cr (+25% YoY); EBITDA INR209 cr (+36% YoY, +22% QoQ); PAT INR106 cr (+41% YoY, +22% QoQ). Specialty Chemicals EBITDA margin 26%, Nutrition margin 15%.
Growth catalysts
CDMO and Fine Chemicals Pipeline Commercialization
Pharma intermediate CDMO pipeline expanded over two years with 70% non-Pyridine chemistries. Mgmt targets scaling the business to 4x its size, with initial Phase II/III API intermediate ramp starting this year. Funnel holds 100-plus molecules with INR3,500-plus crore peak revenue potential, including 25 confirmed molecules. Mgmt added 5 new molecules last quarter across pharma, semicon, and personal care.
Quantum: INR 3,500 crore peak annual revenue potential · Timeline: FY27 · Specialty Chemicals · New product
Discussed on the earnings calls of Jun-26, Mar-26, Dec-25.
Innovator Agro CDMO Contract Ramp-up
Supplies commenced partial volumes in Q1 FY27, with sequential expansion scheduled for Q2 FY27. Take-or-pay contract structure protects the communicated 20%+ EBITDA margin threshold. Supplies commenced in March 2026 with partial volumes in Q1 due to customer-requested pauses. Q2 FY27 volumes will expand sequentially, with take-or-pay protection covering communicated EBITDA targets.
Quantum: 20% plus EBITDA margin threshold · Timeline: Q2 FY27 · Specialty Chemicals · Capacity
Discussed on the earnings calls of Jun-26, Dec-25.
5 more growth catalysts on the Stocksigma ELITE plan.
Guidance & timelines
- Chemical Intermediates EBITDA Share: Around INR100-odd crore, representing roughly 15% of total annual EBITDA. (Timeline: FY27)
- First Half FY27 EBITDA Target: Around INR400 crore plus in EBITDA for H1 FY27. (Timeline: H1 FY27)
3 more guidance items on ELITE.